Ipsen Inks Radiopharmaceutical Licensing Deal With 3B Pharmaceuticals
This article was originally published in Scrip
Ipsen is entering into an exclusive licensing agreement with Germany's 3B Pharmaceuticals GmbH that will see it develop and commercialize novel oncology radiopharmaceuticals that target the neurotensin receptor. The move is part of Ipsen's strategy to focus on niche oncology indications and radiopharmaceuticals.
Register for our free email digests: